ATI-2231 in Advanced Solid Tumor Malignancies

NCT05791474 | Withdrawn Phase 1 DMC FDA Drug

• 1 other identifier: 202306048
• Study Type: interventional
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purpose of this first-in-human study is to test ATI-2231 in advanced solid tumor malignancies with the goal of establishing the recommended Phase II dose of ATI-2231.

Conditions

Advanced Solid Tumor; Advanced Solid Tumor Malignancies

Keywords

MK2 inhibitor; ATI-2231

Outcome Measures

Primary Outcomes (1)

• Number of participants experiencing adverse events

  -Graded per CTCAE v. 5.0

  From baseline through 30 days after end of treatment (estimated to be 7 months)

Secondary Outcomes (17)

• Changes in ATI-2231 pharmacokinetics (PK) as measured by time to peak drug concentration (Tmax)

  Pre-dose cycle 1 day 1, 1 hour, 2 hours, 4 hours, 6 hours, 10 hours, 24 hours, 30 hours, and 48 hours post dose cycle 1 day 1 (estimated to be 2 days)

• Changes in ATI-2231 pharmacokinetics (PK) as measured by elimination rate constant

  Pre-dose cycle 1 day 1, 1 hour, 2 hours, 4 hours, 6 hours, 10 hours, 24 hours, 30 hours, and 48 hours post dose cycle 1 day 1 (estimated to be 2 days)

• Changes in ATI-2231 pharmacokinetics (PK) as measured by apparent volume of distribution

  Pre-dose cycle 1 day 1, 1 hour, 2 hours, 4 hours, 6 hours, 10 hours, 24 hours, 30 hours, and 48 hours post dose cycle 1 day 1 (estimated to be 2 days)

• Changes in ATI-2231 pharmacokinetics (PK) as measured by apparent clearance

  Pre-dose cycle 1 day 1, 1 hour, 2 hours, 4 hours, 6 hours, 10 hours, 24 hours, 30 hours, and 48 hours post dose cycle 1 day 1 (estimated to be 2 days)

• Changes in ATI-2231 pharmacokinetics (PK) as measured by peak concentration (Cmax)

  Pre-dose cycle 1 day 1, 1 hour, 2 hours, 4 hours, 6 hours, 10 hours, 24 hours, 30 hours, and 48 hours post dose cycle 1 day 1 (estimated to be 2 days)

Study Arms (1)

ATI-2231 monotherapy dose escalation

EXPERIMENTAL

* Patients will receive single agent ATI-2231 at assigned dose levels (n=3-6 per dose level). Starting dose of 20 mg by mouth twice per day. * Each cycle is 21 days

Drug: ATI-2231

Interventions

ATI-2231 DRUG

Provided by Aclaris Therapeutics, Inc.

ATI-2231 monotherapy dose escalation

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Biopsy-proven advanced solid tumor malignancy including head and neck cancer, non-small cell lung cancer, gastrointestinal adenocarcinoma, pancreatic adenocarcinoma, prostate cancer, bladder cancer, and breast cancer.
• Eligible patients must have an advanced solid malignancy above, for which standard curative or palliative therapies do not exist or are no longer effective.
• Measurable or non-measurable but evaluable disease by RECIST v 1.1.
• Patients must have archival tissue sample available from prior metastatic biopsy. If no tissue is available, patient may still be able to enroll with PI approval.
• At least 18 years of age.
• ECOG performance status ≤ 2
• Life expectancy of at least 12 weeks.
• Adequate bone marrow and organ function as defined below:
• Leukocytes ≥ 3 K/cumm
• Absolute neutrophil count (ANC) ≥ 1.5 K/cumm
• Platelets ≥ 100 K/cumm
• Total bilirubin ≤ 1.5 x IULN (unless patient has known Gilberts disease)
• AST(SGOT)/ALT(SGPT) ≤ 3.0 x IULN
• Creatinine clearance \> 60 mL/min by Cockcroft-Gault
• The effects of ATI-2231on the developing human fetus are unknown. For this reason, women of childbearing potential and men who are heterosexually active must agree to use adequate contraception as specified in the protocol. Contraception should continue for 1 month (for women) or 3 months (for men) after the end of treatment. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.

You may not qualify if:

• Patients may not have received the following investigational or SOC therapies within the below specified time frames prior to C1D1:
• Denosumab or bisphosphonates within 4 weeks
• Radiation therapy within 1 week
• Systemic chemotherapy, including antibody drug conjugates with chemotherapy payload, within 3 weeks.
• Immunotherapy within 3 weeks
• Oral chemotherapy or molecularly targeted therapy within 5 half-lives of the agent.
• Endocrine therapies do not have a required washout and may be continued until C1D1.
• Untreated brain metastases. Patients with treated brain metastases are eligible if they show no evidence of progression and are off steroids or on stable/decreasing steroid dose.
• A history of allergic reactions attributed to compounds of similar chemical or biologic composition to ATI-2231.
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
• Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry.
• Patients with known HIV are eligible unless their CD4+ T-cell counts are \< 350 cells/mcL or they have a history of AIDS-defining opportunistic infection within the 12 months prior to registration. Concurrent treatment with effective ART according to DHHS treatment guidelines is recommended.
• Screening resting QTcF above 460 ms (average of triplicate).

Sponsors & Collaborators

• Washington University School of Medicine: lead
• Aclaris Therapeutics, Inc.: collaborator

Related Links

• Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Study Officials

• Cynthia X Ma, M.D., Ph.D.

  Washington University School of Medicine

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 31, 2023
• First Posted: March 30, 2023
• Study Start: November 15, 2023
• Primary Completion: June 30, 2025
• Study Completion: June 30, 2025
• Last Updated: November 29, 2023

Record last verified: 2023-11

Data Sharing

• IPD Sharing: Will share
• Time Frame: After the publication
• Access Criteria: Please email cynthiaxma@wustl.edu for requests.